Seasonal Allergic Rhinitis clinical trials

Explore recruiting seasonal allergic rhinitis clinical trials.

Recruiting seasonal allergic rhinitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Seasonal Allergic Rhinitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by birch pollen exposure

Austria, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

Slovakia, Czechia, Bulgaria, Romania, Poland, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Seasonal Allergic Rhinitis trials by city

Seasonal Allergic Rhinitis in Toronto Seasonal Allergic Rhinitis in Vancouver Seasonal Allergic Rhinitis in Montreal Seasonal Allergic Rhinitis in Calgary Seasonal Allergic Rhinitis in Edmonton Seasonal Allergic Rhinitis in Ottawa Seasonal Allergic Rhinitis in Winnipeg Seasonal Allergic Rhinitis in Quebec City Seasonal Allergic Rhinitis in Hamilton Seasonal Allergic Rhinitis in Kitchener Seasonal Allergic Rhinitis in London Seasonal Allergic Rhinitis in Halifax Seasonal Allergic Rhinitis in New York Seasonal Allergic Rhinitis in Los Angeles Seasonal Allergic Rhinitis in Chicago Seasonal Allergic Rhinitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease